targeted ranpirnase conjugates (Alfacell)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nametargeted ranpirnase conjugates (Alfacell)

Drug Alias NameOnconase-mAb conjugate (Alfacell/NCI)rRNP-EGFtargeted Onconase conjugates (Alfacell)polyanhydride-bound Onconase (Alfacell)ranpirnase-mAb conjugate (Alfacell/NCI) +[8]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionCD22 modulatorsEpidermal growth factor receptor erbB1 modulators

TargetsEpidermal growth factor receptor erbB1CD22

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesTamir Biotechnology Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTamir Biotechnology Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A